The Foster City, California-based biotech said today that its IMerge trial of imetelstat – vying to become the first telomerase inhibitor to reach the market – hit its objectives in patients ...
The approval was based on the IMerge trial, which showed that Rytelo significantly improved the proportion of patients in this category who had no need for blood transfusions over a consecutive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback